Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 10/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14420175 | 0.88 | CCR1 (0.49) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL13616996 | 0.78 | CCR1 (0.55) | CCR1CHRM2CCR5 | |
| SCHEMBL653939 | 0.77 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2R | |
| SCHEMBL653940 | 0.77 | CCR1 (0.59) | CCR1CHRM2CCR5TBXA2R | |
| SCHEMBL654072 | 0.75 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL13804506 | 0.75 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL654071 | 0.75 | CCR1 (0.50) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL10287676 | 0.74 | CCR1 (0.54) | CCR1CHRM2CCR5TBXA2RTBXAS1 | |
| SCHEMBL18896076 | 0.74 | CCR1 (0.53) | CCR1CHRM2CCR5TBXA2R | |
| SCHEMBL18633825 | 0.72 | CCR1 (0.52) | CCR1CHRM2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732459-B2 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080139602-A1 | CCR1 antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139602-A1 | CCR1 antagonists and methods of use therefor | CCR1, CCRL2, CCR4 | CCR1 1/4885CHRM2 1238/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.